GlassScriptPhysician profile
Asma Syeda
NPI 1497310122
$655.57
in general payments reported to CMS, 2019-2025
13 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.24 · 2024: $129 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.41 | 2024-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $122.19 | 2025 | |
| Xeris Pharmaceuticals, INC. | $76.14 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $50.34 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $49.29 | 2023-2025 | |
| Novo Nordisk INC | $48.73 | 2024-2025 | Rybelsus |
| Lilly USA, LLC | $47.78 | 2025 | Zepbound, Mounjaro |
| Sequel Med Tech, LLC | $36.64 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $25.48 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $24.33 | 2025 | Unithroid |
| Insulet Corporation | $20.01 | 2025 | Omnipod |
| Abbott Laboratories | $17.12 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $14.11 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Syeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.